牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has filed Prospectus Supplement No. 7, amending and supplementing the original prospectus dated June 26, 2023, for the resale of 492,400 ordinary shares represented by 1,231 American Depositary Shares by selling shareholders. This supplement incorporates information from the company's Form 6-Ks filed on December 29, 2023, and February 23, 2024. Additionally, Biodexa announced the appointment of Ann Merchant as a non-executive director effective December 31, 2023. Merchant brings extensive experience from her previous roles at MorphoSys AG, Schreiner Medipharm, and Amgen Inc., and currently serves on the board of Alvotech S.A. Biodexa also released positive top-line results from a Phase I clinical trial for MTX110 in treating diffuse midline glioma, with a median overall survival of 16.5 months compared to 10.0 months...Show More
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has filed Prospectus Supplement No. 7, amending and supplementing the original prospectus dated June 26, 2023, for the resale of 492,400 ordinary shares represented by 1,231 American Depositary Shares by selling shareholders. This supplement incorporates information from the company's Form 6-Ks filed on December 29, 2023, and February 23, 2024. Additionally, Biodexa announced the appointment of Ann Merchant as a non-executive director effective December 31, 2023. Merchant brings extensive experience from her previous roles at MorphoSys AG, Schreiner Medipharm, and Amgen Inc., and currently serves on the board of Alvotech S.A. Biodexa also released positive top-line results from a Phase I clinical trial for MTX110 in treating diffuse midline glioma, with a median overall survival of 16.5 months compared to 10.0 months in a comparable cohort. The company is preparing for a Phase IIa study of tolimidone for Type 1 diabetes, despite inconclusive preclinical results for beta cell proliferation. Biodexa's shares are traded on the NASDAQ under the symbol 'BDRX', with a closing price of $1.36 as of February 27, 2024. The date of the Prospectus Supplement is February 28, 2024.
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已提交第7號招股說明書補充文件，對2023年6月26日的原始招股說明書進行了修訂和補充，要求出售股東轉售由1,231股美國存托股代表的492,400股普通股。本補充文件納入了該公司於2023年12月29日和2024年2月23日提交的6-K表格中的信息。此外，Biodexa宣佈任命安·默特爲非執行董事，自2023年12月31日起生效。Merchant 以前在 MorphoSys AG、Schreiner Medipharm 和 Amgen Inc. 任職期間擁有豐富的經驗，目前在 Alvotech S.A. 的董事會任職...展開全部
臨床階段的生物製藥公司Biodexa Pharmaceuticals PLC已提交第7號招股說明書補充文件，對2023年6月26日的原始招股說明書進行了修訂和補充，要求出售股東轉售由1,231股美國存托股代表的492,400股普通股。本補充文件納入了該公司於2023年12月29日和2024年2月23日提交的6-K表格中的信息。此外，Biodexa宣佈任命安·默特爲非執行董事，自2023年12月31日起生效。Merchant 以前在 MorphoSys AG、Schreiner Medipharm 和 Amgen Inc. 任職期間擁有豐富的經驗，目前在 Alvotech S.A. 的董事會任職。Biodexa 還公佈了治療瀰漫性中線神經膠質瘤的 I 期臨床試驗的積極成果，總體存活期中位數爲 16.5 個月，而同類群體的總存活率爲 10.0 個月。MTX110儘管β細胞增殖的臨床前結果尚無定論，但該公司仍在爲託利米酮治療1型糖尿病的IIa期研究做準備。Biodexa的股票在納斯達克上市，股票代碼爲 “BDRX”，截至2024年2月27日，收盤價爲1.36美元。招股說明書補充文件的發佈日期爲2024年2月28日。
有用
沒用